It is clear that the expression of RANKL and its receptor RANK play important roles in bone remodeling (bone resorption and bone formation) as well as in breast cancer, prostate cancer, renal cancer, and malignant melanoma. Here, TNFRSF11A is linked to renal carcinoma.